Abstract：Objective To understand and analyze the clinical characteristics，diagnosis and treatment current situation of rheumatic immune diseases in our hospital，so as to provide reference for the treatment of rheumatic immune diseases in Wuyuan area.Methods From June 11，2016 to June 11，2017，altogether 86 cases of rheumatoid arthritis（RA）and gout registered by our department inChinese rheumatism data center（CRDC）were selected as the research objects，and the national population of RA and gout during the same period were selected as the control.Clinical characteristics and diagnosis and treatment of the two were summarized.Results The age of onset，the age of diagnosis，the number of moderate/severe proportion and the follow-up rate of RA patients in our hospital were higher than those in the data center.The age of onset，the age of diagnosis and the rate of persistent attack of gout patients in our hospital were higher than those in the data center.The follow-up rate and the incidence rate of complications of gout patients in our hospital were similar to those in the data center.The utilization rates of Methotrexate，Hydroxychloroquine and Yunke in RA patients in our hospital were higher than those in the data center，and the utilization rates of Febuxostat and Colchicine of gout patients in our hospital were higher than those in the data center.Conclusion The main clinical characteristics of rheumatic immune disease are high age of onset，more male patients than female，and most patients are complicated with gouty stones.At present，immunosuppressive drugs are mainly used to treat rheumatic immune disease.The diagnosis and treatment behavior should be standardized，patient education should be done well，and follow-up rate should be improved to delay the progress of patients′condition to prevent complications.
基金资助:江西省卫生计生委科技计划项目（20187303）
引用本文:
黄志饶. 我院风湿免疫疾病患者的临床特点及诊治现状分析[J]. 中国当代医药, 2019, 26(6): 35-38转71.
HUANG Zhi-rao. Current situation analysis of clinical characteristics and diagnosis and treatment of rheumatic immune diseases in the observation group. 中国当代医药, 2019, 26(6): 35-38转71.
Li M，Tian X，Zhang W，et al.CRDC：a Chinese rheumatology research platform［J］.Clin Rheumatol，2015，34（8）：1347-1352.
［2］
Li M，Tian X，Zhang W，et al.AB1143 Chinese Rheumatism Data Center （CRDC）：the rheumatology research platform in China［J］.Ann Rheumatic Dis，2015，74（S2）：1284.
京公网安备 11010502046607号